Teva has launched in the US the first generic rival to Lundbeck’s Sabril (vigatrabin) 500mg tablets, three weeks after receiving approval from the US Food and Drug Administration (FDA) for the product.
No other company currently holds an approved abbreviated new drug application (ANDA) referencing Sabril tablets.




